What is the maximum recommended daily dose of lamotrigine (Lamictal) for an adult with bipolar disorder, and what class of medication is it?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 6, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Maximum Dose and Drug Class of Lamotrigine (Lamictal) for Bipolar Disorder

Lamotrigine is a mood stabilizer (specifically an anticonvulsant/antiepileptic agent) with a standard maximum dose of 200 mg/day for bipolar disorder, though doses up to 400 mg/day may be used when co-administered with enzyme-inducing medications like carbamazepine. 1, 2, 3

Drug Classification

Lamotrigine is classified as an anticonvulsant mood stabilizer that works by inhibiting sodium and calcium channels in presynaptic neurons, leading to neuronal membrane stabilization. 2, 3

Standard Dosing for Bipolar Disorder

  • Target maintenance dose: 200 mg/day achieved through slow titration over 6 weeks to minimize risk of serious rash including Stevens-Johnson syndrome 2, 3, 4
  • The dosage is titrated gradually over a 6-week period specifically to reduce the incidence of serious rash, which occurs in approximately 0.1% of patients with bipolar disorder 2, 3

Dose Adjustments Based on Comedications

Critical dosing modifications are required based on drug interactions:

  • With valproate (Depakote): Reduce lamotrigine to a maximum of 100 mg/day due to valproate's inhibition of lamotrigine metabolism 4
  • With enzyme inducers (carbamazepine, phenytoin, phenobarbital): Increase lamotrigine up to a maximum of 400 mg/day due to enhanced metabolism 2, 3, 4

Clinical Role in Bipolar Disorder

Lamotrigine is FDA-approved for maintenance therapy in bipolar I disorder and is particularly effective for preventing depressive episodes, NOT for treating acute mania. 1, 5, 2, 3

  • Lamotrigine significantly delays time to intervention for depressive episodes compared to placebo in maintenance therapy 2, 3
  • It has NOT demonstrated efficacy in treating acute mania and should only be initiated after acute mood symptoms are stabilized with lithium, valproate, or atypical antipsychotics 1, 2, 3
  • Lithium was superior to lamotrigine for preventing manic/hypomanic episodes 2, 3

Therapeutic Drug Monitoring

Unlike lithium, lamotrigine generally does not require routine serum level monitoring, though therapeutic drug monitoring data suggests that lower serum concentrations (mean 3,341 ng/ml) may be effective for bipolar disorder compared to the epilepsy therapeutic range of 3,000-14,000 ng/ml. 2, 6

Safety Profile

  • Most common adverse events: headache, nausea, infection, and insomnia 2, 3
  • Serious rash incidence: 0.1% in bipolar disorder studies, including one case of mild Stevens-Johnson syndrome 2, 3
  • Lamotrigine does not cause weight gain, unlike many other mood stabilizers and atypical antipsychotics 2, 3
  • Lower incidence of diarrhea and tremor compared to lithium 2, 3

Critical Safety Warning

If lamotrigine is discontinued for more than 5 days, restart with the full titration schedule rather than resuming the previous dose to minimize risk of serious rash. 1

Common Pitfalls to Avoid

  • Never rapid-load lamotrigine – this dramatically increases the risk of Stevens-Johnson syndrome, which can be fatal 1
  • Do not use lamotrigine as monotherapy for acute mania – it has no demonstrated efficacy for this indication 2, 3
  • Always verify comedications before prescribing, as valproate and enzyme inducers require significant dose adjustments 2, 3, 4
  • Lamotrigine should be combined with an antimanic agent (lithium or atypical antipsychotic) in patients with a history of severe and repeated manic episodes, even during maintenance therapy 4

References

Guideline

First-Line Treatment of Bipolar Disorder

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Treatment of Bipolar Disorder

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.